BenchSci raises $95M series D funding to enable drug discovery innovation at scale with its groundbreaking AI platform ASCEND

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

BenchSci, a world leader in AI solutions for preclinical life sciences research and development (R&D), recently announced a $95 million (US $70 million) Series D funding to expand their AI drug discovery platform ASCEND™, enabling scientists to discover biological connections, dramatically reduce trial-and-error experimentation and uncover risks early.

Arsheen Kaur
Previous

Cubresa installs first BrainPET Insert System at Lawson Health Research Institute
Next

Swift Medical announces proven outcomes across 20 million wound assessments